Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

In vivo assessment of equine arteritis virus vaccine improvement by disabling the deubiquitinase activity of papain-like protease 2

Puck B. van Kasterena, Robert C.M. Knaapa, Paul van den Elzenb, Eric J. Snijdera, Udeni B.R. Balasuriyac, Erwin van den Bornb, Marjolein Kikkerta,*

a Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
b MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands
c Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, 1400 Nicholasville Road, 40546-0099 Lexington, KY, USA

1. Introduction

Arteriviruses are a family of positive-stranded RNA viruses that includes the prototypic equine arteritis virus (EAV) and porcine reproductive and respiratory syndrome virus (PRRSV). Although several vaccines against these viruses are commercially available there is room for improvement, especially in the case of PRRSV. The ability of arteriviruses to counteract the immune response is thought to decrease the efficacy of the current modified live virus vaccines. We have recently shown that the deubiquitinase (DUB) activity of EAV papain-like protease 2 (PLP2) is important for the inhibition of innate immune activation during infection. A vaccine virus lacking PLP2 DUB activity may therefore be more immunogenic and provide improved protection against subsequent challenge than its DUB-competent counterpart. To test this hypothesis, twenty Shetland mares were randomly assigned to one of three groups. Two groups were vaccinated, either with DUB-positive (n = 9) or DUB-negative (n = 9) recombinant EAV. The third group (n = 2) was not vaccinated. All horses were subsequently challenged with the virulent KY84 strain of EAV. Both vaccine viruses proved to be replication competent in vivo. In addition, the DUB-negative virus provided a similar degree of protection against clinical disease as its DUB-positive parental counterpart. Owing to the already high level of protection provided by the parental virus, a possible improvement due to inactivation of PLP2 DUB activity could not be detected under these experimental conditions. Taken together, the data obtained in this study warrant further in vivo investigations into the potential of using DUB-mutant viruses for the improvement of arterivirus vaccines.

* Corresponding author. Tel.: +31 71 526 1442.
E-mail address: m.kikkert@lumc.nl (M. Kikkert).

http://dx.doi.org/10.1016/j.vetmic.2015.04.018
0378-1135/© 2015 Elsevier B.V. All rights reserved.
PCR amplified using Pfu hexamer primers. The PLP2-encoding region was subsequently Minus reverse transcriptase (RT) (Fermentas) and random before and after vaccination. Before vaccination, viral RNA was presence or absence of PLP2 mutations was established, both sequenced. After vaccination, viral RNA present in the blood of previously described (Zhang et al., 2012).

2. Methods

2.1. Cells and viruses

BHK-21 cells were cultured in Glasgow minimum essential medium (Lonza) supplemented with 5% foetal bovine serum (FBS), 10% tryptose phosphate broth, and 10 mM Hepes (pH 7.4). Primary equine lung fibroblasts (ELFs) were cultured in minimum essential medium (Lonza) supplemented with 10% FBS and grown on collagen-coated plastics for a maximum of 10 passages. Vero cells were cultivated in proprietary cell culture medium (MSD Animal Health) supplemented with 1% FBS. All culture media contained 100 U/ml of penicillin and 100 mg/ml of streptomycin or neomycin.

The cloning and production of the DUB-competent (in our previous publication referred to as “wild-type”) and DUB-negative (T312A/I313V/I353R, amino acid numbering based on polyprotein) viruses (strain Bucyrus; EAN551) that were used for vaccination were described previously (van Kasteren et al., 2013). Both viruses have been thoroughly characterized in cell culture experiments, revealing no differences in replication kinetics, yet a strongly decreased DUB activity and an enhanced induction of interferon beta mRNA expression (a hallmark of innate immune activation) of the mutant virus compared to its parental counterpart (van Kasteren et al., 2013). Viral titres were determined by standard plaque assay on ELFs. For experimental challenge, we used the virulent Kentucky 1984 (KY84) strain of EAV, which has been previously described (Zhang et al., 2012).

To confirm the use of the correct virus for vaccination, the presence or absence of PLP2 mutations was established, both before and after vaccination. Before vaccination, viral RNA was isolated from the produced virus stocks using the QI Amp viral RNA mini kit (Qiagen) and converted to cDNA using RevertAid H Minus reverse transcriptase (RT) (Fermentas) and random hexamer primers. The PLP2-encoding region was subsequently PCR amplified using Pfu DNA polymerase (Fermentas) and sequenced. After vaccination, viral RNA present in the blood of four horses from each of the vaccinated groups at 4 days post vaccination was subjected to sequencing. This was done essentially as described above with the exception that the RT reaction on whole blood total RNA (see below) was performed using a primer that recognizes the EAV genome and thus specifically converts the limited amount of viral RNA present in the samples to cDNA. Primer sequences are available upon request.

2.2. Experimental vaccination and challenge of horses

The experiment was performed in accordance with European Community guidelines and national laws on animal experiments. The design of the experiment was approved by the MSD Animal Health’s Committee on the Ethics of Animal Experiments (Dierexperimentencommissie), which is required by national legislation to include both MSD Animal Health employees and independent members, prior to the start of the trial (Permit Number: EXP 12.059). All efforts were made to minimize animal discomfort.

Twenty female Shetland horses (Equus ferus caballus; average age 7.5 ± 5.1 years) that tested negative for EAV-neutralizing antibodies (antibody titres were determined as described previously, Zhang et al., 2012) before the start of the experiment were randomly assigned to one of three treatment groups. After a one-week acclimatization period, horses in Group 1 (n = 9) and Group 2 (n = 9) received an intramuscular (cervical muscle) vaccination of 1 ml phosphate-buffered saline containing 1 × 10^7 plaque-forming units (PFU) of parental or PLP2 DUB-negative EAV, respectively. Horses in Group 3 (n = 2) were not vaccinated and were included in the study one week before challenge. At 34 days post vaccination (dpv), all horses were challenged by intranasal inoculation with 1 × 10^9 PFU of EAV KY84 in a total volume of 5 ml phosphate-buffered saline.

Given the fact that the viruses used for vaccination qualify as genetically modified organisms (GMO), vaccinated horses were kept in VBL3 containment during the entire experiment. All horses were housed in groups, but Group 1 horses were kept separate from Group 2 horses to prevent any cross-contamination. Horses from Group 3 were divided among the two stables upon inclusion, without having direct contact with Group 1 or 2 horses. Water was provided ad libitum and standard feeding procedures were applied.

The general health status of the animals was checked by a veterinarian before vaccination as well as before challenge, and daily by animal care-takers during the entire course of the experiment. In addition, clinical signs were recorded daily from 0 to 14 days post challenge (dpv) and scored according to Table 1. Rectal temperatures were taken daily from 0 to 14, and at 21 and 28 dpv, and daily from 0 to 14, and at 21 and 27 dpv. Blood samples for serum and total RNA isolation were taken every other day between 0 and 14, and at 21 and 28 dpv, and every other day between 0 and 14, and at 21 and 27 dpv. Animals were euthanized according to standard procedures at 61 dpv (27 dpv). For a schematic overview of the experimental set-up see Fig. 1.

2.3. Virus neutralization assay

Blood for serum neutralizing antibody analysis was collected in 8 ml Vacutette Serum Clot Activator Tubes (Greiner Bio-One) and incubated for at least 4 h at room temperature to allow for clotting. Serum samples were subsequently collected by centrifugation at

| Clinical sign | Score/day | Total score (average per animal/day) |
|---------------|-----------|-------------------------------------|
| Bio-One | | |

| Group 1 | Group 2 | Group 3 |
|---------|---------|---------|
| 38 [0.28] | 48 [0.36] | 101 [3.4] |
were challenged with moderately virulent EAV KY84. The experiment ended at 61 dpv. Blood samples for serum and total RNA isolation were taken at the indicated days (lower arrows).

Blood RNA Tubes (Greiner Bio-One) using the MagMAX for 2.4. Quantitative reverse transcriptase PCR assay

dilution at which no CPE was observed. (CPE) by visual inspection. The EAV neutralizing antibody titre was determined during the course of the experiment and did not show an increase upon challenge. In the unvaccinated controls, neutralizing antibody titres could be detected in both Groups 1 and 2 from 6 dpv onwards and no difference in titres was observed between the two groups (Fig. 2B). Titres remained stable longer than the mild temperature increase observed after vaccination. Neutralizing antibodies could be detected in both Groups 1 and 2 from 6 dpv onwards and no difference in titres was observed between the two groups (Fig. 2B). Titres remained stable during the course of the experiment and did not show an increase upon challenge. In the unvaccinated controls, neutralizing antibody titres could be detected at 8 days post challenge (dpc) and reached similar titres as observed after vaccination.

From 0 to 14 dpc, clinical signs (including for example fever, nasal secretions, and loss of appetite) were recorded daily for each animal. An overall clinical signs score was subsequently determined for each animal by scoring these clinical signs according to Table 1. For example, a horse that has reduced appetite on day 5, mucopurulent eye discharge and a temperature of 39 °C on day 8, and no abnormalities on any of the other days has an overall clinical signs score of 4 (1 + 2 + 1). This resulted in an average score per animal per day of 0.28 (±0.02, Group 1) and 0.36 (±0.22, Group 2), which did not differ significantly between the two groups (Student's t-test; \( p > 0.05 \), Table 2). The horses in Group 3 reached an average score of 3.4 (±0.33) per animal per day, which is consistent with the fact that these animals had not been vaccinated. Thus, vaccination with either virus provided a similar high degree of protection against clinical disease.

3. Results

3.1. Vaccine viruses do not differ in the induction of fever or neutralizing antibodies

Vaccination

Group 1: EAV-551A/B PLP2 DUB-competent (n=9)
Group 2: EAV-551A/B PLP2 DUB-negative (n=9)
Group 3: Non-vaccinated Controls (n=2)

Challenge

Group 1: EAV KY84 (n=9)
Group 2: EAV KY84 (n=9)
Group 3: EAV KY84 (n=2)

End of Trial

Fig. 1. Schematic representation of the animal trial. Twenty female Shetland horses were randomly assigned to one of three groups. At the start of the experiment, horses from Groups 1 and 2 (\( n = 9 \) each) were vaccinated with PLP2 DUB-competent or DUB-negative EAV, respectively. Horses in Group 3 (\( n = 2 \)) were not vaccinated. At 34 dpc, all horses were challenged with moderately virulent EAV KY84. The experiment ended at 61 dpc. Blood samples for serum and total RNA isolation were taken at the indicated days (lower arrows).

To determine EAV neutralizing antibody titres in the serum, a virus neutralization assay was performed. Briefly, duplicate two-fold serial dilutions (1:2 to 1:4096) of serum samples were made in 96-well plates and mixed with a 50% tissue culture infective dose (TCID50) of 800 of EAV030 (van Dinten et al., 1997). After a 1-h incubation at 37 °C, 1.2 × 10⁵ Vero cells were added to each well. Plates were subsequently incubated for 4 days at 37 °C after which each well was scored (positive or negative) for cytopathic effect (CPE) by visual inspection. The EAV neutralizing antibody titre was finally determined as the reciprocal value of the highest serum dilution at which no CPE was observed.

2.4. Quantitative reverse transcriptase PCR assay

Total RNA was isolated from whole blood collected in Tempus Blood RNA Tubes (Greiner Bio-One) using the MagMAX for Stabilized Blood Tubes RNA isolation kit (Life Technologies) according to the manufacturer’s instructions. Isolated RNA was converted to cDNA using RevertAid H M Inus reverse transcriptase (Fermentas) and oligo(dT)₂₀ primer. Samples were subsequently analyzed by quantitative reverse-transcriptase (qRT) PCR on a CFX384 Touch Real-Time PCR detection system (BioRad) using iTaq Sybr Green Supermix (BioRad). Primers targeting mRNAs encoding equine β-actin (NM_001081838, 5'-CCACGCGATCTGGCTTG-G-3', 5'-ACCGCTCGTGGCGATGTTG-3'), ISG15 (XM_001496658, 5'-GGAATTCTCGTGCGGCTGAAA-3', 5'-CACTTTGCTTGACGAACACAC-3'), and MX1 (NM_001082492, 5'-GGCGCACAGCCTGCAAGAT-3', 5'-GGGCTCCGCTCCTGGAGAT-3'), or EAV RNA (NC_002532 and AF107279, 5'-GGTGCAGCGCAGCGGTAACA-3', 5'-GGTGGCCCGCCTCCTGGCTCTGTGAT-3') were designed using Primer3 (Rozen and Skaletsky, 1998). The EAV-specific primer set amplifies cDNA derived from both genomic and subgenomic viral mRNAs and the forward primer includes one mismatch with KY84. The real-time PCR program was performed in triplicate, starting with 3 min at 95 °C, 30 s at 65 °C, followed by 40 cycles at 95 °C for 10 s, 65 °C for 10 s, and 72 °C for 30 s. All runs included a standard dilution series and were followed by a melting-curve analysis to confirm the identity of the reaction products.

3.2. PLP2 DUB-negative vaccine virus appears to replicate slightly less efficiently than parental virus in vivo

We then assessed viral replication from 0 to 10 dpc by performing real-time qRT-PCR analysis on total RNA isolated from whole blood. As can be seen in Fig. 3A, all vaccinated horses showed viral replication which, on average, peaked at 4 dpc in both horses were randomly assigned to one of three groups. Animals from two groups were subsequently vaccinated intramuscularly with cell culture-adapted DUB-competent (Group 1, \( n = 9 \)) or DUB-negative (Group 2, \( n = 9 \)) EAV. Horses from Group 3 (\( n = 2 \)) were not vaccinated and served as challenge controls. All horses were intranasally challenged with virulent EAV KY84 at 34 dpc. A schematic representation of the experimental set-up including timing of vaccination, challenge, and sampling is depicted in Fig. 1. The identity of the virus used for vaccination was confirmed by sequencing of viral RNA isolated from whole blood at 4 dpc for a subset of four horses per group from Groups 1 and 2 (data not shown).
groups. Whereas viral RNA could be detected on multiple days in all Group 1 horses (DUB-competent vaccine), in four Group 2 horses (DUB-negative vaccine), viral RNA could only be detected on a single day, i.e. 4 dpv. In addition, when comparing the average amounts of viral RNA between groups at each day post vaccination, these were consistently lower in Group 2 compared to Group 1. However, this difference was only statistically significant at 10 dpv (Student’s t-test; p < 0.05).

Upon challenge with the virulent EAV KY84 strain, both non-vaccinated control horses (Group 3) showed virus replication, with amounts of viral RNA reaching levels comparable to those produced by the vaccine viruses (Fig. 3A). In contrast, amounts of challenge virus RNA remained below the detection limit of the assay in all vaccinated horses from Groups 1 and 2. This result was consistent with the observed appearance of neutralizing antibodies after vaccination in all horses and the low clinical sign scores in both vaccinated groups after challenge.

3.3. No major differences between vaccine viruses in the induction of ISG15 and MX1 mRNA expression could be detected in RNA extracted from whole blood

Finally, we assessed the induction of an innate immune response by parental and PLP2 DUB-negative virus from 0 to 10 dpv by means of real-time qRT-PCR on RNA extracted from whole blood. Since we were unable to detect mRNA encoding type I interferons (a hallmark of innate immune activation), we instead focussed on two highly expressed interferon-stimulated genes encoding ISG15 and MX1, respectively. Both of these genes showed an approximately 2-log increase of expression at 2 dpv, which did not significantly differ between animals from Groups 1 and 2 (Fig. 3B and C). At 6 and 8 dpv, the expression of ISG15 and MX1 mRNA was significantly lower in the animals vaccinated with the PLP2 DUB-negative virus (Group 2) than in those vaccinated with the parental virus (Group 1) (Student’s t-test; p < 0.05), which

Table 2

| Horse ID | Total score | Score/day | Horse ID | Total score | Score/day | Horse ID | Total score | Score/day |
|----------|-------------|-----------|----------|-------------|-----------|----------|-------------|-----------|
| 1        | 5           | 0.33      | 11       | 2           | 0.13      | 10       | 54          | 3.6       |
| 2        | 2           | 0.13      | 12       | 10          | 0.67      | 20       | 47          | 3.1       |
| 3        | 0           | 0.00      | 13       | 4           | 0.27      |          |             |           |
| 4        | 4           | 0.27      | 14       | 4           | 0.27      |          |             |           |
| 5        | 0           | 0.00      | 15       | 7           | 0.47      |          |             |           |
| 6        | 3           | 0.20      | 16       | 3           | 0.20      |          |             |           |
| 7        | 8           | 0.53      | 17       | 1           | 0.07      |          |             |           |
| 8        | 9           | 0.60      | 18       | 7           | 0.47      |          |             |           |
| 9        | 7           | 0.47      | 19       | 10          | 0.67      |          |             |           |

Average 4.2 (±3.3) 0.28 (±0.02) Average 5.3 (±3.3) 0.36 (±0.22) Average 50.5 (±4.9) 3.4 (±0.33)
might be explained by the slight decrease in replication efficiency of the former virus.

4. Discussion

We have previously shown that mutant EAV lacking PLP2 DUB activity induces a more potent innate immune response than its DUB-competent parental virus upon infection in cell culture (van Kasteren et al., 2013), and hypothesized that this feature might be included in an improved arterivirus vaccine. In order to assess whether a PLP2 DUB-negative vaccine virus provides better protection than its DUB-competent counterpart against challenge with a virulent EAV strain, we performed a vaccination-challenge trial in horses. The data obtained in this study showed that in contrast to what was previously seen in cell culture experiments (van Kasteren et al., 2013), the PLP2 mutant virus appears to replicate slightly less efficiently than its parental virus in vivo (Fig. 3A). Even though the DUB-negative virus is clearly replication competent, this finding does suggest a role for PLP2 DUB activity in supporting replication in vivo, e.g., by inhibiting the innate immune response. In addition, despite this slight decrease in replication efficiency, the levels of protection against clinical disease (Table 2), the antibody response (Fig. 2B), and the innate immune response (assessed based on the expression of two interferon-stimulated genes; Fig. 3B and C) induced by the PLP2 DUB-negative virus was comparable to that induced by the parental virus. Surprisingly, we did not observe an increase in EAV-neutralizing antibody titres upon challenge infection of vaccinated animals (Fig. 2B). A possible explanation for this finding is that the virus dose used for challenge was too low, resulting in its efficient clearance before (re-)activation of the antibody response. Taken together, the present study could not be used to substantiate (or refute) our hypothesis that a DUB-negative virus provides better protection against challenge than its DUB-positive counterpart. The main reason for this seems to be the fact that the parental virus already provides a very high degree of protection, which as it turned out could not be detectably improved using this experimental set-up. In hindsight, one solution might have been to perform a more severe challenge, for example by using a higher virus dose for inoculation or a more heterologous and/or virulent strain than KY84. As PRRSV vaccines are in general less efficacious than EAV vaccines, another option would be to perform a similar trial with a PRRSV vaccine in pigs, but this will first require the design of viable PRRSV PLP2 DUB-negative mutants.

In contrast to what was previously found in cell culture-based assays (van Kasteren et al., 2013), we did not detect an increased activation of innate immunity by the PLP2 DUB-negative virus compared to its parental virus in vivo. However, it needs to be noted that we have thus far assessed the expression of only two interferon-stimulated genes, whereas many more exist. It therefore remains a possibility that differences do exist in the expression of other interferon-stimulated genes. Similarly, the induction of interferon-stimulated genes is only one of several consequences of the activation of innate immune signalling. It therefore remains possible that the DUB-negative vaccine virus differs from the parental virus in some other respect pertaining to immunity, for example the activation of cell-mediated adaptive immunity. Also, PLP2 DUB activity likely constitutes only one of several innate immune evasion strategies employed by arteriviruses. For example, nonstructural protein 1 (nsp1) of EAV was recently shown to inhibit the induction of interferon beta in a luciferase reporter assay (Go et al., 2014) and the PRRSV nsp4 main protease was recently shown to cleave the innate immune signalling factor NEMO (Huang et al., 2014).
The OTU proteases of nairoviruses have also been found to possess deubiquitinating activity. For example, coronaviruses were shown to harbour DUB activity. In immune evasion, thereby potentially synergistically increasing the overall immunogenicity of the virus.

Details of the animal study, including specific properties of viruses and hosts used. Nevertheless, the apparently limited negative effect on viral replication of PLP2 DUB-mutations does open up possibilities for combining mutations in multiple domains involved in immune evasion, thereby potentially synergistically increasing the overall immunogenicity of the virus.

5. Conclusion

Notably, arteriviruses are not the only group of viruses that were shown to harbour DUB activity. For example, coronaviruses (including SARS- and MERS-CoV) encode papain-like proteases that display DUB activity (for a review, see Mielech et al., 2014). The OTU proteases of nairoviruses have also been found to possess DUB activity (Frias-Staheli et al., 2007). Like arterivirus PLP2, these viral DUBs have been implicated in innate immune evasion (Frias-Staheli et al., 2007; Mielech et al., 2014) and are therefore potential targets for the design of novel vaccines. Interestingly, we have recently been able to show that the DUB and polyprotein processing functions of the papain-like protease encoded by MERS-CoV can also be separated by targeted mutagenesis (Bailey-Elkin et al., 2014). Taken together, the data obtained in this study definitely warrant further in vivo examination of the consequences of knocking out arterivirus PLP2 DUB activity as well as other immune-escape activities to improve vaccine efficacy. The data obtained in such studies could subsequently also be used as preliminary proof of principle for the design of novel vaccines for other viruses, including corona- and nairoviruses.

Conflict of interest statement

MK, EJS, and PBK have filed a provisional patent application that relates to some aspects of this work.

Acknowledgements

We would like to thank the animal caretakers at the MSD-AH animal facility for their efforts. This research was supported in part by the Division of Chemical Sciences of the Netherlands Organization for Scientific Research (NWO-CW) through ECHO grant 700.59.008 to MK and EJS.

References

Bailey-Elkin, B.A., Knaap, R.C., Johnson, G.G., Dalebout, T.J., Ninaber, D.K., van Kasteren, P.B., Breidenbeek, P.J., Snijder, E.J., Kikkert, M., Mark, B.L., 2014. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J. Biol. Chem. 289, 34667–34682.

Balasuriya, U.B., Go, Y.Y., Maclachlan, N.J., 2013. Equine arteritis virus. Vet. Microbiol. 167, 93–122.

Beura, L.K., Sarkar, S.N., Kwon, B., Subramaniam, S., Jones, C., Pattnaik, A.K., Osorio, I.A., 2010. Porcine reproductive and respiratory syndrome virus nonstructural protein Ibeta modulates host innate immune response by antagonizing IFN3 activation. J. Virol. 84, 1574–1584.

Chen, Z., Lawson, S., Sun, Z., Zhou, X., Chen, X., Christopher-Hennings, J., Nelson, E.A., Fang, Y., 2010. Identification of two auto-cleavage products of nonstructural protein 1 (nsp1) in porcine reproductive and respiratory syndrome virus infected cells: nsp1 function as interferon antagonist. Virology 398, 87–97.

Frias-Staheli, N., Giannakou, M., Li, Y., Fang, Y., Balasuriya, U.B., 2011. Crystal structure of the nsp1 protein of porcine reproductive and respiratory syndrome virus. J. Struct. Biol. 175, 365–386.

Han, M., Yu, D., Song, C., Yoo, D., 2013. Ordovis papain-like proteases: multifunctional enzymes with protease, deubiquitinating and de-lysylating activities. Virus Res. 178, 132–137.

Kim, O., Sun, Y., Lamb, C., Yoo, D., 2010. Nonstructural protein 1beta modulates host innate immune response by antagonizing IFN3 activation in immortalized porcine alveolar macrophages. Arch. Virol. 155, 2187–2195.

McCabe, P. J., Roberts, A., Willard, J.E., Carson, G.D., 1987. Response of vaccinated and non-vaccinated mares to artificial insemination with semen from stallions persistently infected with equine arteritis virus. In: Fifth International Conference on Equine Infectious Diseases, 1987, Lexington, KY, pp. 13–18.

Mielech, A.M., Cheng, Y., Mesecar, A.D., Baker, S.C., 2014. Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and de-lysylating activities. Virus Res. 178, 132–137.

van Kasteren, P.B., Bailey-Elkin, B.A., James, T.W., Ninaber, D.K., Beugeling, C., van Dinten, L.C., den Boon, J.A., Wassenaar, A.L., Spaan, W.J., Snijder, E.J., 1997. An infectious arterivirus cDNA clone: identification of a replicase point mutation that abolishes discontinuous mRNA transcription. Proc. Natl. Acad. Sci. U. S. A. 94, 991–996.

van Kasteren, P.B., Bailey-Elkin, B.A., James, T.W., Ninaber, D.K., Beugeling, C., Khajehpour, M., Snijder, E.J., Mark, B.L., Kikkert, M., 2013. Deubiquitinating function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells. Proc. Natl. Acad. Sci. U. S. A. 110, E838–E847.

van Kasteren, P.B., Beugeling, C., Ninaber, D.K., Frias-Staheli, N., van Boheemen, S., Garcia-Sastre, A., Snijder, E.J., Kikkert, M., 2012. Arterivirus and nairoivirus ovarian tumor domain-containing deubiquitinases target activated RIG-I to control innate immune signaling. J. Virol. 86, 773–785.

van Doren, L.C., den Boon, J.A., Wassenaar, A.L., Spaan, W.J., Snijder, E.J., 1997. An infectious arterivirus cDNA clone: identification of a replicase point mutation that abolishes discontinuous mRNA transcription. Proc. Natl. Acad. Sci. U. S. A. 94, 991–996.